Mitchell Glass

Chronic Airway Therapeutics develops treatments for chronic respiratory diseases. The private company is based in Kew East, Australia. The CEO of the Australian company is Mitchell Glass.

Accolade Pharma LLC is a pharmaceutical company that specializes in developing topical formulations and devices for the active ingredient of Accolate® (zafirlukast) to treat allergic inflammation. The private company is based in Wilmington, DE. Leukotriene antagonists modify allergic responses by blocking leukotrienes, which prevents or decreases symptoms of acute inflammation such as wheezing, sneezing, itching, redness, and swelling. The company was founded in 2012 by G. John Mohr, who has been the CEO since 2012.

Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent.

University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA.